|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14.04.26 - 15:18
|
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan (GlobeNewswire EN)
|
|
|
SALT LAKE CITY, April 14, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the use of the MyChoice® Test for prostate cancer patients as a companion diagnostic for Lynparza® (olaparib). With this approval, clinicians can now order the MyChoice Test to determine homologous recombination deficiency (HRD) status for patients with ovarian cancer, and BRCA1/2 status for breast and prostate cancers....
|
|
|
|
|
|
|
14.04.26 - 15:06
|
Build a Six Figure Dividend Stream With Four Blue Chip Names and $2 Million (24/7 Wall St.)
|
|
|
Two million dollars in four household-name dividend payers can generate between $132,000 and $146,000 in annual income. That is the income profile of the moderate yield tier, where Enterprise Products Partners L.P. (NYSE:EPD), Pfizer Inc. (NYSE:PFE), Altria Group (NYSE:MO), and Verizon Communications (NYSE:VZ) currently sit. The real question is whether $2 million is right for ... Build a Six Figure Dividend Stream With Four Blue Chip Names and $2 Million...
|
|
|
14.04.26 - 15:06
|
Linden Lake Labs Applauds Acquisition of Portfolio Company CrossBridge Bio by Eli Lilly and Company (Business Wire)
|
|
|
Transaction validates dual-payload ADC platform and reinforces Linden Lake Labs' life sciences platform for advancing breakthrough therapiesROCKVILLE, Md.--(BUSINESS WIRE)--Linden Lake Labs (“L3”), an early-stage life sciences platform committed to advancing innovative therapies, today announced that its portfolio company, CrossBridge Bio, has entered into a definitive agreement to be acquired by Eli Lilly and Company.
Linden Lake Labs participated in CrossBridge Bio's seed financing round in November 2024, supporting the early development of its differentiated dual-payload antibody-drug conjugate (ADC) platform.
“This milestone reflects the power of investing early in pioneering science and exceptional teams,” said Abhishake Chhibber, Co-Founder of Linden Lake Labs. “At Linden Lake Labs, we are committed to advancing innovative therapies through a life sciences platform—bringing together scientific founders, capital, and strategic capabilities to accelerate breakthrough medicines. CrossBrid...
|
|
|
14.04.26 - 15:06
|
Kashiv BioSciences Strengthens Executive Leadership with New Chief Operating Officer and Senior Vice President of Regulatory Affairs (Business Wire)
|
|
|
PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv”), a vertically integrated biopharmaceutical company, today announced the appointment of Viet Nguyen as Chief Operating Officer and Arlene Wolny as Senior Vice President of Regulatory Affairs. Both leaders will be based in Piscataway, New Jersey.
Viet Nguyen has over two decades of leadership experience, with deep expertise in building high-performing teams, scaling complex operations, and driving commercial readiness across multiple therapeutic modalities. Prior to joining Kashiv, he spent over a decade in international leadership roles across Singapore, China, and Switzerland with leading global organizations including Genentech, Roche, Merck Group, and Bayer Corp. He holds a Bachelor of Science in Pharmacy from Saint Joseph's University and has completed his Global Leadership Management program from INSEAD / Stanford University. As COO, Viet will oversee manufacturing, quality, supply chain, and engineering across global operation...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
